Cargando…

Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy

Ischemic (ICM) and dilated cardiomyopathy (DCM) represent the two main underlying heart diseases in patients referred for catheter ablation of ventricular tachycardia (VT). While VT ablation in ischemic cardiomyopathy is relatively well-studied, data in patients with DCM are still scarce. The study...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakarov, Ivaylo, Mueller, Julian, Ene, Elena, Berkovitz, Arthur, Sonne, Kai, Nentwich, Karin, Schupp, Tobias, Behnes, Michael, Deneke, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323762/
https://www.ncbi.nlm.nih.gov/pubmed/35887764
http://dx.doi.org/10.3390/jcm11144000
_version_ 1784756632901648384
author Chakarov, Ivaylo
Mueller, Julian
Ene, Elena
Berkovitz, Arthur
Sonne, Kai
Nentwich, Karin
Schupp, Tobias
Behnes, Michael
Deneke, Thomas
author_facet Chakarov, Ivaylo
Mueller, Julian
Ene, Elena
Berkovitz, Arthur
Sonne, Kai
Nentwich, Karin
Schupp, Tobias
Behnes, Michael
Deneke, Thomas
author_sort Chakarov, Ivaylo
collection PubMed
description Ischemic (ICM) and dilated cardiomyopathy (DCM) represent the two main underlying heart diseases in patients referred for catheter ablation of ventricular tachycardia (VT). While VT ablation in ischemic cardiomyopathy is relatively well-studied, data in patients with DCM are still scarce. The study aimed to compare the acute and long-term outcomes in patients with ICM and DCM who underwent VT ablation at a high-volume center. Consecutive patients who underwent VT ablation from April 2018 to April 2021 were included retrospectively. Patients with ischemic cardiomyopathy were compared to those with dilated cardiomyopathy. The primary endpoint was rate of VT recurrences, the secondary endpoints included overall mortality, rehospitalization because of cardiac condition (VT, acute heart failure, acute myocardial infarction, heart transplantation or implantation of left ventricular assisting device), and major adverse cardiac events (MACE) at long-term follow-up. A total of 225 patients admitted for first VT ablation were included. A total of 156 patients (69%) revealed ICM and 69 (31%) DCM. After a mean follow-up of 22 months, the primary endpoint of VT recurrence occurred significantly more often in the patients with dilated cardiomyopathy (ICM n = 47; 37% vs. DCM n = 34; 64%; p = 0.001). In regard to the secondary endpoint of overall mortality, there was no difference between the two patient cohorts (DCM n = 9; 15% vs. ICM n = 22; 16%; p = 0.677); the patients with DCM showed significantly higher rehospitalization rates due to cardiac conditions (75% vs. 59%; p = 0.038) and more frequent MACE (68% vs. 52%; p= 0.036). In a Cox regression model, electrical storm at admission was shown to be a predictor for VT recurrence after successful catheter ablation (HR = 1.942: 95% CI 1.237–3.050; p = 0.004), while the ablation of every induced VT morphology during the procedure (HR = 0.522; 95% CI = 0.307–0.885; p = 0.016) contributed to a positive long-term outcome. DCM is associated with a higher risk of VT recurrence after catheter ablation compared to ICM. Furthermore, patients with DCM are more frequent re-hospitalized in the majority of cases due the VT recurrence. There is no difference in the long-term mortality between the two cohorts.
format Online
Article
Text
id pubmed-9323762
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93237622022-07-27 Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy Chakarov, Ivaylo Mueller, Julian Ene, Elena Berkovitz, Arthur Sonne, Kai Nentwich, Karin Schupp, Tobias Behnes, Michael Deneke, Thomas J Clin Med Article Ischemic (ICM) and dilated cardiomyopathy (DCM) represent the two main underlying heart diseases in patients referred for catheter ablation of ventricular tachycardia (VT). While VT ablation in ischemic cardiomyopathy is relatively well-studied, data in patients with DCM are still scarce. The study aimed to compare the acute and long-term outcomes in patients with ICM and DCM who underwent VT ablation at a high-volume center. Consecutive patients who underwent VT ablation from April 2018 to April 2021 were included retrospectively. Patients with ischemic cardiomyopathy were compared to those with dilated cardiomyopathy. The primary endpoint was rate of VT recurrences, the secondary endpoints included overall mortality, rehospitalization because of cardiac condition (VT, acute heart failure, acute myocardial infarction, heart transplantation or implantation of left ventricular assisting device), and major adverse cardiac events (MACE) at long-term follow-up. A total of 225 patients admitted for first VT ablation were included. A total of 156 patients (69%) revealed ICM and 69 (31%) DCM. After a mean follow-up of 22 months, the primary endpoint of VT recurrence occurred significantly more often in the patients with dilated cardiomyopathy (ICM n = 47; 37% vs. DCM n = 34; 64%; p = 0.001). In regard to the secondary endpoint of overall mortality, there was no difference between the two patient cohorts (DCM n = 9; 15% vs. ICM n = 22; 16%; p = 0.677); the patients with DCM showed significantly higher rehospitalization rates due to cardiac conditions (75% vs. 59%; p = 0.038) and more frequent MACE (68% vs. 52%; p= 0.036). In a Cox regression model, electrical storm at admission was shown to be a predictor for VT recurrence after successful catheter ablation (HR = 1.942: 95% CI 1.237–3.050; p = 0.004), while the ablation of every induced VT morphology during the procedure (HR = 0.522; 95% CI = 0.307–0.885; p = 0.016) contributed to a positive long-term outcome. DCM is associated with a higher risk of VT recurrence after catheter ablation compared to ICM. Furthermore, patients with DCM are more frequent re-hospitalized in the majority of cases due the VT recurrence. There is no difference in the long-term mortality between the two cohorts. MDPI 2022-07-11 /pmc/articles/PMC9323762/ /pubmed/35887764 http://dx.doi.org/10.3390/jcm11144000 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chakarov, Ivaylo
Mueller, Julian
Ene, Elena
Berkovitz, Arthur
Sonne, Kai
Nentwich, Karin
Schupp, Tobias
Behnes, Michael
Deneke, Thomas
Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy
title Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy
title_full Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy
title_fullStr Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy
title_full_unstemmed Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy
title_short Long-Term Outcomes after Catheter Ablation of Ventricular Tachycardia in Dilated vs. Ischemic Cardiomyopathy
title_sort long-term outcomes after catheter ablation of ventricular tachycardia in dilated vs. ischemic cardiomyopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323762/
https://www.ncbi.nlm.nih.gov/pubmed/35887764
http://dx.doi.org/10.3390/jcm11144000
work_keys_str_mv AT chakarovivaylo longtermoutcomesaftercatheterablationofventriculartachycardiaindilatedvsischemiccardiomyopathy
AT muellerjulian longtermoutcomesaftercatheterablationofventriculartachycardiaindilatedvsischemiccardiomyopathy
AT eneelena longtermoutcomesaftercatheterablationofventriculartachycardiaindilatedvsischemiccardiomyopathy
AT berkovitzarthur longtermoutcomesaftercatheterablationofventriculartachycardiaindilatedvsischemiccardiomyopathy
AT sonnekai longtermoutcomesaftercatheterablationofventriculartachycardiaindilatedvsischemiccardiomyopathy
AT nentwichkarin longtermoutcomesaftercatheterablationofventriculartachycardiaindilatedvsischemiccardiomyopathy
AT schupptobias longtermoutcomesaftercatheterablationofventriculartachycardiaindilatedvsischemiccardiomyopathy
AT behnesmichael longtermoutcomesaftercatheterablationofventriculartachycardiaindilatedvsischemiccardiomyopathy
AT denekethomas longtermoutcomesaftercatheterablationofventriculartachycardiaindilatedvsischemiccardiomyopathy